Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-interventional Prospective Descriptive Study to Assess the Impact on Patient´s Well-being of Fixed-time Duration (FTD) and Continuous Oral Regimens for Newly Diagnosed and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain

NCT06125795 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06125795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06125795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-interventional Prospective Descriptive Study to Assess the Impact on Patient´s Well-being of Fixed-time Duration (FTD) and Continuous Oral Regimens for Newly Diagnosed and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain
Lead sponsor
AbbVie
Phase
Observational
Overall status
Active, not recruiting
Start date
November 6, 2023
Completion date
July 31, 2026
Enrollment
146 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia